<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="372179">
  <stage>Registered</stage>
  <submitdate>17/01/2017</submitdate>
  <approvaldate>20/02/2017</approvaldate>
  <actrnumber>ACTRN12617000261314</actrnumber>
  <trial_identification>
    <studytitle>Blood Ropivacaine level after PECS II block in patients undergoing mastectomy.</studytitle>
    <scientifictitle>A prospective study of analgesic efficacy and plasma Ropivacaine concentration after PECS II block in patients undergoing mastectomy.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>breast cancer</healthcondition>
    <healthcondition>regional block</healthcondition>
    <healthcondition>mastectomy</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Venous blood will be sampled from the blood taking canulla at 0, 10, 20, 30, 45, 60, 90, and 120 minutes after PECS II block using Ropivacaine.</interventions>
    <comparator>No control group</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To measure the chronological changes in venous concentration of Ropivacaine after PECS II block.

</outcome>
      <timepoint>venous concentration of Ropivacaine at 0, 10, 20, 30, 45, 60, 90, 120 minutes after PECS II block.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Calculation for the time point of maximum concentration of Ropivacaine occurred (Tmax) after injection of PECS II block, </outcome>
      <timepoint>within two hours after injection of PECS II block.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Calculation of maximum venous plasma concentration (Cmax).</outcome>
      <timepoint>within two hours after injection of PECS II block.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>hypodermic needle will be used to test the dermatological extent of the block 30 minutes after Ropivacaine injection.
</outcome>
      <timepoint>dermatological extent of the block 30 minutes after Ropivacaine injection.
</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>to assess the block duration of the analgesic effect post operation.
</outcome>
      <timepoint>The duration of the block will be evaluated by measuring the amount of time that elapsed between completion of the block and the first administration of postoperative rescue analgesia (subcutaneous Morphine 0.1mg/kg).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>adult female patients undergoing unilateral mastectomy with axillary clearance will be prospectively enrolled.
Inclusion criteria:
-	ASA 1, 2 and 3 (without significant liver or renal impairment) 
-	Age above 18 years old
-	Able to give consent
-	Body weight &gt; 50kg
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-	Patients refusal and inability to give consent or cooperation during procedure
-	Allergy or sensitivity to local anaesthetics
-	BMI&gt;35
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>patient undergoing unilateral mastectomy and agreeable for PECS II block will be offered to participate in the study.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate />
    <actualstartdate>1/01/2017</actualstartdate>
    <anticipatedenddate>30/06/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>28</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/06/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University Malaya</primarysponsorname>
    <primarysponsoraddress>Faculty of Medicine
University of Malaya
50603 Kuala Lumpur
Malaysia</primarysponsoraddress>
    <primarysponsorcountry>Malaysia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University Malaya Medical Center</fundingname>
      <fundingaddress>Anaesthesiology Department,
University Malaya Medical Center, 
Lembah Pantai,
59100 
Kuala Lumpur,
Malaysia</fundingaddress>
      <fundingcountry>Malaysia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To measure the chronological changes in venous concentration of Ropivacaine after PECS II block, in which the calculation for the time point of maximum concentration of Ropivacaine occurred (Tmax) and maximum venous plama concentration (Cmax) are mandatory. This would determine whether the peak plasma Ropivacaine concentration level is within the safety level allowed. The venous threshold value of systemic toxicity is 2.2 microgram/ml. The result of this study might change future recommended dosing regimen for PECS II block practice using Ropivacaine. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>UMMC Medical Research Ethics Committee (MREC)</ethicname>
      <ethicaddress>University Malaya Medical Centre
Lembah Pantai,59100
Kuala Lumpur, Malaysia.</ethicaddress>
      <ethicapprovaldate>3/06/2016</ethicapprovaldate>
      <hrec>20165-2443</hrec>
      <ethicsubmitdate>6/05/2016</ethicsubmitdate>
      <ethiccountry>Malaysia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Mohd Shahnaz Bin Hasan</name>
      <address>Department of Anaethesiology
Faculty of Medicine
University of Malaya
50603 Kuala Lumpur
Malaysia</address>
      <phone>+6079492052</phone>
      <fax />
      <email>shahnaz@ummc.edu.my</email>
      <country>Malaysia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Mohd Shahnaz Bin Hasan</name>
      <address>Department of Anaethesiology
Faculty of Medicine
University of Malaya
50603 Kuala Lumpur
Malaysia</address>
      <phone>+6079492052</phone>
      <fax />
      <email>shahnaz@ummc.edu.my</email>
      <country>Malaysia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Mohd Shahnaz Bin Hasan</name>
      <address>Department of Anaethesiology
Faculty of Medicine
University of Malaya
50603 Kuala Lumpur
Malaysia</address>
      <phone>+6079492052</phone>
      <fax />
      <email>shahnaz@ummc.edu.my</email>
      <country>Malaysia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Mohd Shahnaz Bin Hasan</name>
      <address>Department of Anaethesiology
Faculty of Medicine
University of Malaya
50603 Kuala Lumpur
Malaysia</address>
      <phone>+6079492052</phone>
      <fax />
      <email>shahnaz@ummc.edu.my</email>
      <country>Malaysia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>